Janux Therapeutics, Inc.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Feb 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $10.3M | — | $3.7M | — | — | — | $10.0M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $31.0M | — | $26.8M | — | — | — | $34.6M |
| SG&A Expense | — | $11.0M | — | $11.1M | — | — | — | $10.6M |
| Operating Income | — | $-31.7M | — | $-34.2M | — | — | — | $-35.3M |
| Operating Margin | — | -308.7% | — | -916.5% | — | — | — | -352.5% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-22.0M | — | $-24.4M | — | — | — | $-24.3M |
| Net Margin | — | -214.0% | — | -652.6% | — | — | — | -243.1% |
| EPS (Basic) | — | $-0.35 | — | $-0.39 | — | — | — | $-0.39 |
| EPS (Diluted) | — | $-0.35 | — | $-0.39 | — | — | — | $-0.39 |
| Shares Outstanding (Basic) | 61.1M | 62.9M | 61.0M | 62.7M | 60.8M | 60.4M | 60.1M | 62.0M |
| Shares Outstanding (Diluted) | 61.1M | 62.9M | 61.0M | 62.7M | 60.8M | 60.4M | 60.1M | 62.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |